Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fusion Pharmaceuticals Inc (NQ: FUSN ) 21.55 UNCHANGED Last Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Fusion Pharmaceuticals Inc < Previous 1 2 3 4 Next > FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024 May 07, 2024 FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Top 4 Health Care Stocks That May Plunge This Month April 26, 2024 Via Benzinga Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market April 25, 2024 The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. Via Investor's Business Daily AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost April 11, 2024 AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA... Via Benzinga Exposures Product Safety AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race April 02, 2024 AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... Via Benzinga Recap: Fusion Pharmaceuticals Q4 Earnings March 20, 2024 Via Benzinga Unveiling 11 Analyst Insights On Fusion Pharmaceuticals March 20, 2024 Via Benzinga Kuehn Law Encourages FUSN, KAMN, DRQ, and VZIO Investors to Contact Law Firm March 19, 2024 --News Direct-- Via News Direct FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023 March 20, 2024 FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results March 19, 2024 U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. The Dow traded up 0.63% to 39,034.59 while the NASDAQ rose 0.35% to 16,160.20. The... Via Benzinga Topics Stocks Exposures US Equities Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Via Benzinga A Glimpse Into The Expert Outlook On Fusion Pharmaceuticals Through 7 Analysts March 04, 2024 Via Benzinga Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts January 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session March 19, 2024 Via Benzinga Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results March 19, 2024 U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.54% to 39,001.22 while the NASDAQ fell 0.34% to 16,048.51. The S&P 500... Via Benzinga Topics Stocks Exposures US Equities National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Nasdaq Down 100 Points; US Housing Starts Surge In February March 19, 2024 U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 19, 2024 Via Benzinga Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover March 19, 2024 The company is working on radiopharmaceuticals treatments for cancer. Via Investor's Business Daily Why Is Greenwave Tech Solutions (GWAV) Stock Down 53% Today? March 19, 2024 Greenwave Tech Solutions stock is falling on Tuesday following an update on warrants for GWAV stock and other news this morning. Via InvestorPlace Nvidia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday March 19, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Why Is Ontrak (OTRK) Stock Up 105% Today? March 19, 2024 Ontrak stock is on the rise Tuesday as OTRK investors are excited about an upcoming live fireside chat set for later today. Via InvestorPlace Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket March 19, 2024 Shares of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) rose sharply in today’s pre-market trading after the company agreed to be acquired by AstraZeneca for around $2 billion in cash. Via Benzinga Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today? March 19, 2024 Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3. Via InvestorPlace US Stocks Poised For Lower Open As Fed Jitters Dampen Tech Hopes; Oil Rally Pauses, Bitcoin Slides 8% March 19, 2024 Interest-rate concerns seem to be impacting market sentiment as stock futures indicate a slightly lower opening on Tuesday. Via Benzinga Topics Economy Exposures Interest Rates Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday March 19, 2024 Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning! Via InvestorPlace AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments March 19, 2024 AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... Via Benzinga 7 Low-Cost Call Options With High-Profit Potential February 19, 2024 Call options are exciting but they can be a bit confusing. Let me guide you to compelling opportunities among certain hot names. Via InvestorPlace Fusion Pharmaceuticals - Already Discovered By Wall Street February 06, 2024 Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Via Talk Markets 12 Health Care Stocks Moving In Friday's After-Market Session January 19, 2024 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.